Immunovant, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IMVT research report →
About the company
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody.
- CEO
- Eric Venker
- IPO
- 2019
- Employees
- 362
- HQ
- New York City, NY, US
Price Chart
- Market Cap
- $7.96B
- P/E
- -13.95
- P/S
- 0.00
- P/B
- 9.27
- EV/EBITDA
- -13.98
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -68.16%
- ROIC
- -62.50%
- Revenue
- $0 · 0.00%
- Net Income
- $-505,606,000 · -22.17%
- EPS
- $-2.77 · -1.47%
- Op Income
- $-532,902,000
- FCF YoY
- -8.15%
- 52W High
- $39.28
- 52W Low
- $14.32
- 50D MA
- $31.99
- 200D MA
- $25.71
- Beta
- 0.77
- Avg Volume
- 1.93M
Get TickerSpark's AI analysis on IMVT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 26, 26 | Gloria Melanie | sell | 14,748 |
| Jun 26, 26 | Gloria Melanie | sell | 2,966 |
| Jun 26, 26 | Stout Jay S | sell | 33,277 |
| Jun 26, 26 | Stout Jay S | sell | 6,723 |
| Jun 26, 26 | Van Tuyl Christopher | other | 17,824 |
| Jun 26, 26 | Van Tuyl Christopher | sell | 14,982 |
| Jun 26, 26 | Van Tuyl Christopher | sell | 2,842 |
| Jun 26, 26 | Van Tuyl Christopher | other | 17,824 |
| Jun 26, 26 | Girao Tiago | other | 10,000 |
| Jun 26, 26 | Girao Tiago | other | 10,000 |
Our IMVT coverage
Recent articles, reports, and earnings notes.
No research on IMVT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IMVT report →Similar companies
Peers in the same neighborhood.